Shenfu Injection (参附注射液) inhibits inflammation in patients with acute myocardial infarction complicated by cardiac shock

Yan-yan Jin; Hai Gao; Xin-yong Zhang; Hui Ai; Xiao-lin Zhu; Jing Wang

doi:10.1007/s11655-016-2749-x

Your Location：

Home >

Browse articles >

Shenfu Injection (参附注射液) inhibits inflammation in patients with acute myocardial infarction complicated by cardiac shock

OriginalPaper | Updated：2021-08-27

- Shenfu Injection (参附注射液) inhibits inflammation in patients with acute myocardial infarction complicated by cardiac shock
- Shenfu Injection (参附注射液) inhibits inflammation in patients with acute myocardial infarction complicated by cardiac shock
- 中国结合医学杂志（英文版） 2017年23卷第3期页码：170-175
- Affiliations：
  
  Emergency and Critical Care Center, Beijing Anzhen Hospital, Capital Medical University,Beijing,China
- Author bio：
- Funds：
  
  Supported by Beijing Chinese Medicine Technology Development Surfaces Subject of Special Funds (No. JJ2013-19)
- DOI：10.1007/s11655-016-2749-x
  中图分类号：
- 纸质出版日期：2017，
  
  网络出版日期：2016-12-27，
Scan for full text
Jin, Yy., Gao, H., Zhang, Xy. et al. Shenfu Injection (参附注射液) inhibits inflammation in patients with acute myocardial infarction complicated by cardiac shock., Chin. J. Integr. Med. 23, 170–175 (2017). https://doi.org/10.1007/s11655-016-2749-x

Yan-yan Jin, Hai Gao, Xin-yong Zhang, et al. Shenfu Injection (参附注射液) inhibits inflammation in patients with acute myocardial infarction complicated by cardiac shock[J]. Chinese Journal of Integrative Medicine, 2017,23(3):170-175.
Jin, Yy., Gao, H., Zhang, Xy. et al. Shenfu Injection (参附注射液) inhibits inflammation in patients with acute myocardial infarction complicated by cardiac shock., Chin. J. Integr. Med. 23, 170–175 (2017). https://doi.org/10.1007/s11655-016-2749-x DOI：

Yan-yan Jin, Hai Gao, Xin-yong Zhang, et al. Shenfu Injection (参附注射液) inhibits inflammation in patients with acute myocardial infarction complicated by cardiac shock[J]. Chinese Journal of Integrative Medicine, 2017,23(3):170-175. DOI： 10.1007/s11655-016-2749-x.

摘要

To investigate the effect of Shenfu Injection (参附注射液

SFI) on inflammatory factors in patients with acute myocardial infarction complicated by cardiogenic shock (CS) treated with and intra-aortic balloon pump (IABP). This study enrolled 60 patients with ST-segment elevation myocardial infarction (STEMI) complicated by CS. Patients underwent IABP and emergency percutaneous coronary intervention (PCI) were randomly divided into two groups by random number table with 30 cases in each group

one given Sfitreatment (100 mL/24 h)

one not. The two groups were then compared in a clinical setting for left ventricular function

biochemical indicators and Inflammatory factors

including C-reactive proteins (CRP)

interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α). Major adverse cardiac and cerebrovascular events (MACCE) events were compared between patients of the two groups both in-hospital and in follow-ups. The IABP support treatment times of patients in the IABP+Sfigroup were signifificantly shorter than the IABP group (52.87±28.84 vs. 87.45±87.31

P=0.047). In the patients of the IABP+Sfigroup

the CRP peak appeared in 24 h after PCI operation. The CRP peak in the patients of the IABP+Sfigroup was signifificantly lower than that in the IABP group (31.27±3.93 vs. 34.62±3.47

P=0.001). The increases in range of TNF-α in the patients of the IABP+Sfigroup were signifificantly lower than those of the IABP group (182.29±22.79 vs. 195.54±12.02

P=0.007). The increases in range of IL-1 in the patients of the IABP+Sfigroup were signifificantly lower than those of the IABP group (214.98±29.22 vs. 228.60±7.03

P=0.019). The amplitude elevated TNF-α 72 h after admission was an independent risk factor of in-hospital MACCE events (OR 0.973

95% CI 0.890–0.987

P=0.014) in patients with STEMI and CS. Patients with STEMI complicated by CS treated by IABP and Sfihad a reduced inflammatory reaction

a reduced dependence of CS on IABP and shortened the course of disease.

Abstract

To investigate the effect of Shenfu Injection (参附注射液

one given Sfitreatment (100 mL/24 h)

one not. The two groups were then compared in a clinical setting for left ventricular function

biochemical indicators and Inflammatory factors

including C-reactive proteins (CRP)

P=0.047). In the patients of the IABP+Sfigroup

the CRP peak appeared in 24 h after PCI operation. The CRP peak in the patients of the IABP+Sfigroup was signifificantly lower than that in the IABP group (31.27±3.93 vs. 34.62±3.47

P=0.001). The increases in range of TNF-α in the patients of the IABP+Sfigroup were signifificantly lower than those of the IABP group (182.29±22.79 vs. 195.54±12.02

P=0.007). The increases in range of IL-1 in the patients of the IABP+Sfigroup were signifificantly lower than those of the IABP group (214.98±29.22 vs. 228.60±7.03

P=0.019). The amplitude elevated TNF-α 72 h after admission was an independent risk factor of in-hospital MACCE events (OR 0.973

95% CI 0.890–0.987

P=0.014) in patients with STEMI and CS. Patients with STEMI complicated by CS treated by IABP and Sfihad a reduced inflammatory reaction

a reduced dependence of CS on IABP and shortened the course of disease.

关键词

inflflammatory factorcardiac shockintra-aortic balloon pumpChinese MedicineShenfu Injection

Keywords

inflflammatory factorcardiac shockintra-aortic balloon pumpChinese MedicineShenfu Injection

references

Hasdai D, Topol EJ, Califf RM, Berger PB, Holmes DR. Cardiogenic shock complicating acute coronary syndromes. Lancet 2000;356: 749–756.

Thiele H, Allam B, Chatellier G, Schuler G, Lafont A. Shock in acute myocardial infarction: the cape horn for trials. Eur Heart J 2010;31: 1828–1835.

Oconnor CM, Rogers JC. Evidence for overturning the guidelines in cardiogenic shock. N Engl J Med 2012;367: 1349–1350.

Prondizinsky R, Lemm H, Swyter M, Wegener N, Unverzagt S, Carter JM, et al. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicate by cardiogenic shock: the prospective, randmonized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 2010;38: 152–160.

Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003;107: 2998–3002.

Yang QC, Mao W, Liu XS, Bao K, Zou Li C,et al. Systematic review on efficacy and safety of Shenfu Injection for cardiogenic shock. China J Tradit Chin Med Pharm (Chin) 2012;27: 1052–1059.

Qiu ZL, Ye YP, Zhang N. Clinical efficacy of Shenfu Injection in treating severe sepsis and its effects on serum levels of interleukin-6 and interleukin-10. Chin J Integr Tradit West Med (Chin) 2012;32: 348–351.

Zhang BJ, Wang CT, Wang YL. Protective effect of Shenfu Injection against myocardial ischemia and reperfusion injury in rats. Chin J Anesthesiol (Chin) 2005;25: 776–777.

Cao J, Min S. Protective effects of cardioplegic solution containing Shenfu Injection on isolated rabbit heart against ischemia-reperfusion injury. Chin J Anesthesiol (Chin) 2006;26: 61–64.

Ke DZ, Chen QW, Li CHL, Li GQ. Study on cytokine mechanism of Shenfu Injection in treating dogs with cardiogenic shock. China J Chin Mater Med (Chin) 2007;32: 2273–2276.

Roubille F, Cayla G, Plcotm C, Pradet V, Massin F, Gervasoni R, et al. C-reactive protein (CRP) after revascularized STEMI: Is CRP a prognostic factor? Rev Med Intern 2008;29: 868–874.

Shpektor A. Cardiogenic shock: the role of inflammation. Acute Card Care 2010;12: 115–118.

Picariello C, Lazzeri C, Chiostri M, Gensini GF, Valente S. Kinetic of procalcitonin in patients with cardiogenic shock following acute myocardial infarction: preliminary data. HSR Proceedings in Intensive Care and Cardiovascular Anesthesia 2010;2: 201–207.

Gu J, Hu W, Xiao H, Feng X, Chen Y, Zhang D. Intra-aortic balloon pump improves clinical prognosis and attenuates C-reactive protein level in acute STEMI complicated by cardiogenic shock. Cardiology 2010;117: 75–80.

Di Iorio A, Ferrucci L, Sparvieri E, Cherubini A, Volpato S, Corsi A, et al. Serum IL-1beta levels in health and disease: a population-based study. The InCHIANTI study. Cytokine 2003;22: 198–205.

Zhang JX, Cheng X, Liao YH, Lu B, Yang Y, Li B, et al. Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction. Cardiovasc Drugs Ther 2005;19: 13–21.

Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intra-aortic balloon support for myocardial infarction with cardiogenic shock. N Eng J Med 2012;367: 1287–1296.

Chen MQ, Li WH, Shi GX. Research progress of pharmacological effects on the cardiovascular system of ginsenoside Rb. Med Recapit (Chin) 2015;21: 519–521.

Li R. Progress of Shenfu Injection in treating chronic heart failure. Chin J Integr Med Cardio/Cerebrov Dis (Chin) 2014;12: 1257–1260.

Tsounis D, Bouras G, Giannopoulos G, Papadimitriou C, Alexopoulos D, Deftereos S. Inflammation markers in essential hypertension. Med Chem 2014;10: 672–681.

Kim K, Lee JH, Chang HJ, Cho YS, Youn TJ, Chung WY, et al. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circulation 2008;72: 293–298.

Abramson JL, Lewis C, Murrah NV, Anderson GT, Vaccarino V. Relation of C-reactive protein and tumor necrosis factor-alpha to ambulatory blood pressure variability in healthy adults. Am J Cardiol 2006;98: 649–652.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Neuroprotective effect of Shenfu Injection (参附注射液) following cardiac arrest in pig correlates with improved mitochondrial function and cerebral glucose uptake

Therapeutic effects of shenfu injection (参附注射液) on post-cardiac arrest syndrome

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients

Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome